GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter

 
• By Jessica Merrill

Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.

Slowdown, word cube with background.
Sales of GSK's big growth driver Shingrix have slowed in the second quarter • Source: Shutterstock

More from Earnings

More from Business